JP2010526541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526541A5 JP2010526541A5 JP2010507728A JP2010507728A JP2010526541A5 JP 2010526541 A5 JP2010526541 A5 JP 2010526541A5 JP 2010507728 A JP2010507728 A JP 2010507728A JP 2010507728 A JP2010507728 A JP 2010507728A JP 2010526541 A5 JP2010526541 A5 JP 2010526541A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide decoy
- transcription factor
- sequence
- composition
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 54
- 102000040945 Transcription factor Human genes 0.000 claims description 40
- 108091023040 Transcription factor Proteins 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 12
- 102100023226 Early growth response protein 1 Human genes 0.000 claims description 10
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 8
- 102100027313 Calsenilin Human genes 0.000 claims description 8
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims description 8
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims description 8
- 102100032057 ETS domain-containing protein Elk-1 Human genes 0.000 claims description 8
- 102100035075 ETS-related transcription factor Elf-1 Human genes 0.000 claims description 8
- 101000914063 Eucalyptus globulus Leafy/floricaula homolog FL1 Proteins 0.000 claims description 8
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 8
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims description 8
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 8
- 101000726098 Homo sapiens Calsenilin Proteins 0.000 claims description 8
- 101000877395 Homo sapiens ETS-related transcription factor Elf-1 Proteins 0.000 claims description 8
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 claims description 8
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 claims description 8
- 101001139117 Homo sapiens Krueppel-like factor 7 Proteins 0.000 claims description 8
- 101100456626 Homo sapiens MEF2A gene Proteins 0.000 claims description 8
- 101001094741 Homo sapiens POU domain, class 4, transcription factor 1 Proteins 0.000 claims description 8
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 8
- 101001096159 Homo sapiens Pituitary-specific positive transcription factor 1 Proteins 0.000 claims description 8
- 101000881764 Homo sapiens Transcription elongation factor 1 homolog Proteins 0.000 claims description 8
- 101000653735 Homo sapiens Transcriptional enhancer factor TEF-1 Proteins 0.000 claims description 8
- 101000744900 Homo sapiens Zinc finger homeobox protein 3 Proteins 0.000 claims description 8
- 102000043138 IRF family Human genes 0.000 claims description 8
- 108091054729 IRF family Proteins 0.000 claims description 8
- 102100020677 Krueppel-like factor 4 Human genes 0.000 claims description 8
- 102100020692 Krueppel-like factor 7 Human genes 0.000 claims description 8
- 101100079042 Mus musculus Myef2 gene Proteins 0.000 claims description 8
- 102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 claims description 8
- 102100035395 POU domain, class 4, transcription factor 1 Human genes 0.000 claims description 8
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 8
- 102100037914 Pituitary-specific positive transcription factor 1 Human genes 0.000 claims description 8
- 101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 claims description 8
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 claims description 8
- 108010042291 Serum Response Factor Proteins 0.000 claims description 8
- 102100022056 Serum response factor Human genes 0.000 claims description 8
- 101000805921 Strongylocentrotus purpuratus Upstream stimulatory factor Proteins 0.000 claims description 8
- 102100040296 TATA-box-binding protein Human genes 0.000 claims description 8
- 101710145783 TATA-box-binding protein Proteins 0.000 claims description 8
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 claims description 8
- 102100040105 Upstream stimulatory factor 1 Human genes 0.000 claims description 8
- 101000671634 Xenopus borealis Upstream stimulatory factor 1 Proteins 0.000 claims description 8
- 102100039966 Zinc finger homeobox protein 3 Human genes 0.000 claims description 8
- 210000002540 macrophage Anatomy 0.000 claims description 8
- 101150014102 mef-2 gene Proteins 0.000 claims description 8
- 102100031690 Erythroid transcription factor Human genes 0.000 claims description 6
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 claims description 6
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 claims description 6
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 6
- 102100035251 Protein C-ets-1 Human genes 0.000 claims description 6
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 6
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 6
- 230000008055 nociceptive signaling Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- -1 IKZF Proteins 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 102000005869 Activating Transcription Factors Human genes 0.000 claims description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 claims description 2
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 claims description 2
- 102000017679 HTR3A Human genes 0.000 claims description 2
- 101000761343 Homo sapiens 5-hydroxytryptamine receptor 3A Proteins 0.000 claims description 2
- 101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 claims description 2
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 claims description 2
- 101001123678 Homo sapiens Phenylethanolamine N-methyltransferase Proteins 0.000 claims description 2
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims description 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims description 2
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 claims description 2
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 claims description 2
- 102100024611 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 238000000034 method Methods 0.000 description 16
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91758307P | 2007-05-11 | 2007-05-11 | |
| US60/917,583 | 2007-05-11 | ||
| PCT/US2008/063471 WO2008141308A2 (en) | 2007-05-11 | 2008-05-12 | Gene expression and pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014149516A Division JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526541A JP2010526541A (ja) | 2010-08-05 |
| JP2010526541A5 true JP2010526541A5 (OSRAM) | 2012-04-05 |
| JP5646320B2 JP5646320B2 (ja) | 2014-12-24 |
Family
ID=40002879
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507728A Expired - Fee Related JP5646320B2 (ja) | 2007-05-11 | 2008-05-12 | 遺伝子発現と疼痛 |
| JP2014149516A Expired - Fee Related JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
| JP2015207655A Expired - Fee Related JP6082796B2 (ja) | 2007-05-11 | 2015-10-22 | 遺伝子発現と疼痛 |
| JP2016064037A Expired - Fee Related JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
| JP2017106521A Pending JP2017148074A (ja) | 2007-05-11 | 2017-05-30 | 遺伝子発現と疼痛 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014149516A Expired - Fee Related JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
| JP2015207655A Expired - Fee Related JP6082796B2 (ja) | 2007-05-11 | 2015-10-22 | 遺伝子発現と疼痛 |
| JP2016064037A Expired - Fee Related JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
| JP2017106521A Pending JP2017148074A (ja) | 2007-05-11 | 2017-05-30 | 遺伝子発現と疼痛 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US7943591B2 (OSRAM) |
| EP (3) | EP2158316B1 (OSRAM) |
| JP (5) | JP5646320B2 (OSRAM) |
| AU (1) | AU2008251320B2 (OSRAM) |
| CA (1) | CA2723672C (OSRAM) |
| DK (1) | DK2158316T3 (OSRAM) |
| ES (2) | ES2619314T3 (OSRAM) |
| HR (1) | HRP20150759T1 (OSRAM) |
| HU (1) | HUE025701T2 (OSRAM) |
| PL (1) | PL2158316T3 (OSRAM) |
| PT (1) | PT2158316E (OSRAM) |
| SI (1) | SI2158316T1 (OSRAM) |
| WO (1) | WO2008141308A2 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2158316T3 (en) * | 2007-05-11 | 2015-07-20 | Adynxx Inc | Gene expression and pain |
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| IN2012DN00720A (OSRAM) | 2009-07-06 | 2015-06-19 | Ontorii Inc | |
| US8609617B2 (en) | 2009-09-04 | 2013-12-17 | University Of Miami | KLF family members regulate intrinsic axon regeneration ability |
| WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
| MX347361B (es) | 2011-07-19 | 2017-04-12 | Wave Life Sciences Ltd | Metodos para la sintesis de acidos nucleicos funcionalizados. |
| US20130071444A1 (en) | 2011-09-16 | 2013-03-21 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System | Amphiphilic Cationic Polymers and Methods of Use Thereof |
| US9139829B2 (en) * | 2012-02-28 | 2015-09-22 | Medical Diagnostic Laboratories, Llc | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment |
| RU2668136C2 (ru) | 2012-05-10 | 2018-09-26 | Эйдинкс, Инк. | Композиции для доставки активных ингредиентов |
| AU2013287630B2 (en) | 2012-07-13 | 2017-05-25 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| EP2872147B1 (en) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
| GB201310853D0 (en) * | 2013-06-18 | 2013-07-31 | Ucb Pharma Sa | Method |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| CN106068325B (zh) | 2014-01-16 | 2021-07-09 | 波涛生命科学有限公司 | 手性设计 |
| JP6705807B2 (ja) | 2014-08-15 | 2020-06-03 | エーダイニクス インコーポレイテッド | 疼痛を治療するためのオリゴヌクレオチドデコイ |
| EP3348637B1 (en) * | 2015-09-09 | 2022-03-09 | AnGes, Inc. | Chimeric decoy |
| US20200017853A1 (en) * | 2016-02-29 | 2020-01-16 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
| WO2024044770A1 (en) * | 2022-08-26 | 2024-02-29 | Core Biotherapeutics, Inc. | Oligonucleotides for the treatment of breast cancer |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5272056A (en) | 1991-01-03 | 1993-12-21 | The Research Foundation Of State University Of New York | Modification of DNA and oligonucleotides using metal complexes of polyaza ligands |
| US5683985A (en) | 1991-04-18 | 1997-11-04 | The Salk Institute For Biological Studies | Oligonucleotide decoys and methods relating thereto |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| CA2168245A1 (en) | 1993-07-29 | 1995-02-09 | C. Anthony Hunt | Polynucleotide decoys that inhibit mhc-ii expression and uses thereof |
| DE69435100D1 (de) | 1993-10-29 | 2008-06-26 | Brigham & Womens Hospital | Therapeutische verwendung von cis-element-fallen in vivo |
| ATE295367T1 (de) | 1994-11-17 | 2005-05-15 | Taiho Pharmaceutical Co Ltd | Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält |
| AU5369396A (en) | 1995-03-23 | 1996-10-08 | Research Foundation Of The State University Of New York, The | Rest protein and dna |
| US6004813A (en) | 1995-05-11 | 1999-12-21 | Applied Research Systems Ars Holding N.V. | Il-6 activity inhibitor |
| ATE357922T1 (de) | 1995-05-12 | 2007-04-15 | Anges Mg Inc | Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen |
| GB9515356D0 (en) | 1995-07-26 | 1995-09-20 | Medical Res Council | Improvements in or relating to delivery of nucleic acid |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| WO1997044064A2 (en) | 1996-05-20 | 1997-11-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligonucleotides which specifically bind retroviral nucleocapsid proteins |
| US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| JP4215219B2 (ja) | 1997-07-04 | 2009-01-28 | アンジェスＭｇ株式会社 | 脳保護剤 |
| JP3667047B2 (ja) | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
| US6060310A (en) | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
| US6432641B1 (en) | 1997-12-16 | 2002-08-13 | University Of Saskatchewan Technologies Inc. | Conductive metal-containing nucleic acids |
| PL345207A1 (en) | 1998-06-02 | 2001-12-03 | Glaxo Group Ltd | Gene therapy method |
| US6818626B1 (en) | 1998-07-17 | 2004-11-16 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
| US6867289B1 (en) | 1998-10-26 | 2005-03-15 | Board Of Regents, The University Of Texas Systems | Thio-modified aptamer synthetic methods and compositions |
| US6008048A (en) | 1998-12-04 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of EGR-1 expression |
| US7160869B2 (en) | 1998-12-16 | 2007-01-09 | University Of Saskatchewan | Biologically active metal-containing nucleic acids |
| ATE354667T1 (de) | 1998-12-23 | 2007-03-15 | Genentech Inc | Transfectaconen, die kalciumphosphat und eine nucleinsäure enthalten |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6333408B1 (en) | 1999-03-08 | 2001-12-25 | Kureha Chemical Industry Co., Ltd. | Oligonucleotides inhibitors of PAI-1 MRNA |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| US6599741B1 (en) | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
| US6927027B2 (en) | 1999-12-21 | 2005-08-09 | Ingeneus Corporation | Nucleic acid multiplex formation |
| US6969704B1 (en) | 2000-08-25 | 2005-11-29 | The Trustees Of Columbia University In The City Of New York | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject |
| DE10049549A1 (de) | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
| AU2002213198A1 (en) | 2000-10-11 | 2002-04-22 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| US20040077573A1 (en) | 2000-11-24 | 2004-04-22 | Hiroki Maruyama | Method for regulating the activity of an expression product of a gene transferred into living body |
| US20020137715A1 (en) | 2001-01-03 | 2002-09-26 | Alain Mauviel | Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis |
| AU2002241952A1 (en) | 2001-01-22 | 2002-07-30 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
| PT1362600E (pt) | 2001-02-20 | 2008-07-09 | Anges Mg Inc | Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica |
| AU2002254132A1 (en) | 2001-03-06 | 2002-09-19 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
| US20030166555A1 (en) | 2001-04-02 | 2003-09-04 | Alberini Cristina M. | Methods and compositions for regulating memory consolidation |
| EP1298141A1 (en) | 2001-09-27 | 2003-04-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2 |
| DE10148828B4 (de) | 2001-10-04 | 2005-05-19 | Avontec Gmbh | Modulation der Expression STAT-1-abhängiger Gene |
| US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
| CN1697647A (zh) | 2002-02-01 | 2005-11-16 | 奥默罗斯公司 | 用于抑制疼痛,炎症和软骨退化的溶液及方法 |
| CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
| WO2003091432A1 (en) | 2002-04-26 | 2003-11-06 | Anges Mg, Inc. | Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription |
| DE10242319A1 (de) | 2002-09-12 | 2004-03-25 | Avontec Gmbh | Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens |
| WO2004052401A2 (en) | 2002-12-09 | 2004-06-24 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| DE10257421A1 (de) | 2002-12-09 | 2004-07-08 | Grünenthal GmbH | Regulatorische Elemente im 5'-Bereich des VR1-Gens |
| WO2005004702A2 (en) | 2003-06-30 | 2005-01-20 | Massachusetts Institute Of Technology | Egr genes as targets for the diagnosis and treatment of schizophrenia |
| WO2005027830A2 (en) * | 2003-09-12 | 2005-03-31 | Virginia Commonwealth University | Chimeric transcription factor decoy oligonucleotides |
| JP2005336081A (ja) | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤 |
| US7482158B2 (en) | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| US20060293264A1 (en) | 2004-07-22 | 2006-12-28 | Grandis Jennifer R | STAT3 decoy oligonucleotides and uses therefor |
| EP1799271A4 (en) | 2004-09-21 | 2010-05-05 | Anesiva Inc | DISPOSAL OF POLYNUCLEOTIDES |
| RU2584609C2 (ru) | 2004-09-28 | 2016-05-20 | Кварк Фармасьютикалс, Инк. | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности |
| ATE509100T1 (de) | 2004-10-22 | 2011-05-15 | Anges Mg Inc | Chimäre (doppel-) attrappe |
| US7585848B2 (en) | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
| WO2006096498A2 (en) * | 2005-03-04 | 2006-09-14 | Dana-Farber Cancer Institute, Inc. | Regulation of runx1 for treatment of pain |
| US7680060B2 (en) * | 2005-03-08 | 2010-03-16 | Cisco Technology, Inc. | Transferring state information in a network |
| WO2006104913A2 (en) | 2005-03-25 | 2006-10-05 | Medtronic, Inc. | USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN |
| ES2845146T3 (es) | 2006-10-09 | 2021-07-26 | Neurofluidics Inc | Sistema de purificación de líquido cefalorraquídeo |
| EP2146691A2 (en) | 2007-04-17 | 2010-01-27 | Baxter International Inc. | Nucleic acid microparticles for pulmonary delivery |
| DK2158316T3 (en) * | 2007-05-11 | 2015-07-20 | Adynxx Inc | Gene expression and pain |
| SI2605794T1 (sl) | 2010-08-20 | 2017-01-31 | Replicor Inc. | Oligonukleotidni kelatni kompleksi |
| AU2012272908A1 (en) | 2011-06-21 | 2013-12-19 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
| ES2646226T3 (es) | 2011-07-20 | 2017-12-12 | Hospira, Inc. | Composiciones que comprenden diclofenaco para el tratamiento del dolor posoperatorio |
| RU2668136C2 (ru) | 2012-05-10 | 2018-09-26 | Эйдинкс, Инк. | Композиции для доставки активных ингредиентов |
| DK2849798T3 (da) | 2012-05-18 | 2021-05-31 | Replicor Inc | Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder |
| JP6705807B2 (ja) | 2014-08-15 | 2020-06-03 | エーダイニクス インコーポレイテッド | 疼痛を治療するためのオリゴヌクレオチドデコイ |
| US20200017853A1 (en) | 2016-02-29 | 2020-01-16 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
-
2008
- 2008-05-12 DK DK08755344.2T patent/DK2158316T3/en active
- 2008-05-12 HR HRP20150759TT patent/HRP20150759T1/hr unknown
- 2008-05-12 EP EP08755344.2A patent/EP2158316B1/en not_active Not-in-force
- 2008-05-12 CA CA2723672A patent/CA2723672C/en active Active
- 2008-05-12 US US12/119,435 patent/US7943591B2/en not_active Expired - Fee Related
- 2008-05-12 PL PL08755344T patent/PL2158316T3/pl unknown
- 2008-05-12 JP JP2010507728A patent/JP5646320B2/ja not_active Expired - Fee Related
- 2008-05-12 EP EP14179247.3A patent/EP2818550B1/en not_active Not-in-force
- 2008-05-12 SI SI200831461T patent/SI2158316T1/sl unknown
- 2008-05-12 PT PT87553442T patent/PT2158316E/pt unknown
- 2008-05-12 HU HUE08755344A patent/HUE025701T2/en unknown
- 2008-05-12 ES ES14179247.3T patent/ES2619314T3/es active Active
- 2008-05-12 EP EP16199871.1A patent/EP3199635B1/en not_active Not-in-force
- 2008-05-12 AU AU2008251320A patent/AU2008251320B2/en not_active Ceased
- 2008-05-12 WO PCT/US2008/063471 patent/WO2008141308A2/en not_active Ceased
- 2008-05-12 ES ES08755344.2T patent/ES2542511T3/es active Active
-
2011
- 2011-03-15 US US13/048,793 patent/US8093225B2/en not_active Expired - Fee Related
- 2011-12-09 US US13/316,321 patent/US8741864B2/en active Active - Reinstated
-
2014
- 2014-04-22 US US14/258,927 patent/US9290762B2/en not_active Expired - Fee Related
- 2014-07-23 JP JP2014149516A patent/JP5890869B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-22 JP JP2015207655A patent/JP6082796B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-09 US US15/019,791 patent/US10041069B2/en active Active
- 2016-03-28 JP JP2016064037A patent/JP6306075B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-30 JP JP2017106521A patent/JP2017148074A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526541A5 (OSRAM) | ||
| CA2723672C (en) | Gene expression and pain | |
| JP2013510561A5 (OSRAM) | ||
| JP2016014070A5 (OSRAM) | ||
| Shern et al. | Pediatric rhabdomyosarcoma | |
| JP2018534950A5 (OSRAM) | ||
| Deb et al. | Chromatin dynamics: H3K4 methylation and H3 variant replacement during development and in cancer | |
| JP2004537260A5 (OSRAM) | ||
| JP2015534817A5 (OSRAM) | ||
| Duigou et al. | Independent control of replication initiation of the two Vibrio cholerae chromosomes by DnaA and RctB | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| Pumbwe et al. | BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis | |
| JP2015504650A5 (OSRAM) | ||
| JP2016502858A5 (OSRAM) | ||
| JP2012505657A5 (OSRAM) | ||
| Le Grice | Targeting the HIV RNA genome: high-hanging fruit only needs a longer ladder | |
| JP2006518372A5 (OSRAM) | ||
| WO2007146511A3 (en) | Compounds and methods for modulating gene expression | |
| JP2008513513A5 (OSRAM) | ||
| JP2014504857A5 (OSRAM) | ||
| JP2010515707A5 (OSRAM) | ||
| Harvey et al. | Repetitive sequence variations in the promoter region of the adhesin-encoding gene sabA of Helicobacter pylori affect transcription | |
| JP2017529834A5 (OSRAM) | ||
| CN107805643B (zh) | 靶向抑制沙门氏菌耐药外排泵基因acrA的siRNA-DNA纳米系统及其制备方法 | |
| JP2019523302A5 (OSRAM) |